Compounds > ampelopsin
Page last updated: 2024-09-04

ampelopsin and ER-Negative PR-Negative HER2-Negative Breast Cancer

ampelopsin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahmat, N; Gopalsamy, B; Khaza'ai, H; Latifah, SY; Md Hashim, NF; Tieng, FYF; Wibowo, A1
Ahmat, N; Fakurazi, S; Foo, JB; Ong, YS; Rahman, NA; Razali, ZA; Tor, YS; Wibowo, A; Yazan, LS; Yeap, SK1

Other Studies

2 other study(ies) available for ampelopsin and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Ampelopsin E Reduces the Invasiveness of the Triple Negative Breast Cancer Cell Line, MDA-MB-231.
    Molecules (Basel, Switzerland), 2019, Jul-18, Volume: 24, Issue:14

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Survival; Dipterocarpaceae; Flavonoids; Humans; Molecular Structure; Podosomes; Triple Negative Breast Neoplasms

2019
Induction of apoptosis and G2/M arrest by ampelopsin E from Dryobalanops towards triple negative breast cancer cells, MDA-MB-231.
    BMC complementary and alternative medicine, 2016, Sep-08, Volume: 16

    Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Dipterocarpaceae; Flavonoids; Humans; Plant Extracts; Triple Negative Breast Neoplasms

2016